This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CERC611, CERC 611, LY3130418, LY 3130418, LY-3130418
Description: CERC-611 is a potent and selective Transmembrane AMPA Receptor Regulatory Proteins (“TARP”)-gamma 8-dependent AMPA receptor antagonist.
Cerecor and Eli Lilly
In September 2016, Cerecor announced that it has acquired exclusive, worldwide rights from Eli Lilly to develop and commercialize LY3130418 (now designated as CERC-611). Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of CERC-611. Lilly will receive an upfront licensing fee as well as milestone and tiered royalty payments.
Partners: Eli Lilly & Company
Additional information available to subscribers only: